MaaT Pharma plans to advance a global Phase 3 trial [...]
MaaT Pharma has reported its half year 2025 financial results, [...]
MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotech focused on microbiome-based [...]
MaaT Pharma plans to advance a global Phase 3 trial [...]
MaaT Pharma has reported its half year 2025 financial results, [...]
MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotech focused on microbiome-based [...]